![]() |
인쇄하기
취소
|
After Pneumococcal vaccine was selected as a NIP (National Immunization Program) this May, Prevenar 13 of Pfizer and Synflorix of GSK have increased their sales as expected. However, Synflorix has attracted more attention as its market share has increased by 0.5%.
Looking at the market share after the NIP selection, both vaccines have increased their sales as expected. The vaccination became f...